Found 6 matching trials
A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma PHASE1 This study is a single-center, open Phase I study, to observe the effective...
Show More Location
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Learn More & Join Trial
A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2) PHASE1 This study is a multi-center, single-arm clinical study to evaluate the eff...
Show More Location
Anhui Provincial Cancer Hospital
Learn More & Join Trial
A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1) PHASE1 This study is a single-armed, open-label, multicenter Phase 1/2 study to ev...
Show More Location
Anhui Provincial Cancer Hospital
Learn More & Join Trial
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System EARLY_PHASE1 Antibody-mediated inflammatory diseases of the nervous system (also known a...
Show More Location
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Learn More & Join Trial
A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma PHASE1 It is a dose expansion, open-label, phase Ib study to evaluate the safety, ...
Show More Location
The University of Texas MD Anderson Cancer Center
Learn More & Join Trial
A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma. N/A This study is a multicenter, observational, single-arm real world study. Th...
Show More Location
Peking University People's Hospital
Learn More & Join Trial